Provided by Tiger Trade Technology Pte. Ltd.

AKESO

89.900
0.000
Volume:4K
Turnover:333.45K
Market Cap:82.80B
PE:-62.50
High:89.900
Open:89.900
Low:89.900
Close:89.900
52wk High:159.800
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:- -
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.438
ROE:-13.59%
ROA:-4.57%
PB:8.36
PE(LYR):-62.50
PS:20.57

Loading ...

Movement Alert|Akeso Bio Falls 3.75% in Regular Trading, Ivonescimab Global Phase III Interim Analysis Missing Endpoint Continues to Weigh on Valuation

Market Focus
·
May 22

Innovative Drug Sector Rebound Ahead of ASCO Conference: Key ETFs Gain Momentum

Deep News
·
May 21

AKESO Shares Surge Over 7% in Morning Session on Clinical Approval for Cadonilimab in Colon Cancer

Stock News
·
May 21

Stock Track | AKESO Soars 6.61% Intraday on ASCO Abstract Embargo Lifting and Biotech Sector Strength

Stock Track
·
May 21

Movement Alert|Akeso Inc Rises 3.22% in Regular Trading, ASCO Abstract Embargo Lifting Combined with Biotech Sector Rally

Market Focus
·
May 21

Stock Track | Akeso Plummets 5.07% Intraday on Disappointing Ivonescimab Phase III Interim Results

Stock Track
·
May 18

Phase Ii Data From a Randomized Double-Blind Trial of Ligufalimab (Anti-Cd47) Combination Therapy in Frontline Aml Published at Eha 2026

THOMSON REUTERS
·
May 15

AKESO Maintains Stable Capital Structure in April; Issued Shares Steady at 921.14 Million

Bulletin Express
·
May 06

Stock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results

Stock Track
·
May 06

AKESO Shares Climb Over 5% in Morning Session as Institutions Remain Confident in Ivonescimab's Potential Against Keytruda

Stock News
·
May 06

Stock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment

Stock Track
·
May 04

3 Asian Stocks Estimated To Be Up To 31.8% Below Intrinsic Value

Simply Wall St.
·
May 01

AKESO(09926)2025年总收入达305.62亿元分(30.562亿元),双特异抗体商业化与研发并进,净亏损有所扩大

Bulletin Express
·
Apr 29

Akeso reminds non-registered shareholders of switch to electronic corporate communications

Bulletin Express
·
Apr 29

Akeso publishes 2025 ESG report

Reuters
·
Apr 29

Akeso says Phase III HARMONi-2 trial shows ivonescimab beats pembrolizumab on PFS

Reuters
·
Apr 28

AKESO's Cadonilimab Demonstrates Counter-Seasonal Quarterly Growth, Says Bank of America

Stock News
·
Apr 28

Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data

Stock Track
·
Apr 27

Akeso (SEHK:9926) Valuation Check After Positive Cadonilimab Phase II Data In Advanced Pancreatic Cancer

Simply Wall St.
·
Apr 26

BUZZ-HK-listed Akeso slides to 3-week low

Reuters
·
Apr 23